Looking beyond 28-day all-cause mortality.

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Sepsis and Acute Respiratory Distress Syndrome (ARDS). Intervention: Antithrombin III.

Gordon D. Rubenfeld

doi:10.1186/cc1513

January 1, 2002Critical CareOpen Access

Looking beyond 28-day all-cause mortality.

View Full Paper

Ask AI

Bookmark

Share

PICO

P

Population

Sepsis and Acute Respiratory Distress Syndrome (ARDS)

I

Intervention / Comparator

Antithrombin III

Limitations

The clinically significant difference in percentage change in the visual analogue scale used for quality of life is unknown.
Results expressed as change from a critically ill baseline obscure the actual status of patients at each time point.
Informative censoring complicates quality of life analyses when death competes with non-mortality endpoints.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This commentary highlights the methodological challenges, such as informative censoring, in assessing long-term quality of life outcomes in critical care trials.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gordon D. Rubenfeld (2002) conducted an editorial in Sepsis and Acute Respiratory Distress Syndrome (ARDS). Antithrombin III was evaluated.

synapsesocial.com/papers/6a9b7941a7e2c1a1764978c1 https://doi.org/10.1186/cc1513

View Full Paper

Ask AI

Bookmark

Share

Looking beyond 28-day all-cause mortality.

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Looking beyond 28-day all-cause mortality.

PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading